Pacific Biosciences of California, Inc.
Here’s whether Pacific Biosciences of California, Inc. (PACB) is worth buying in 2026 — based on weekly-updated price trend, RSI momentum, and return vs. the S&P 500. Our current read: Caution.
Positives: 50-day MA is rising (+1.62% over 10 days); RSI 56 — healthy momentum range; strong 1-year return of +11.0%. Concerns: trading below the 200-day MA (long-term downtrend); below the 50-day MA (medium-term momentum negative). Currently 52.0% off its 52-week high. Score: +0/7.
PACB is trading below its 200-day MA ($1.68) — a key warning sign the longer-term trend is under pressure. An RSI of 56.2 sits in the neutral zone — momentum is neither stretched nor exhausted. The 1-year return of +11.0% compares to +22.9% for SPY (trailed the market by 11.8%). The current 52.0% drawdown from the 52-week high reflects elevated risk for momentum-based strategies.